Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1 28Phase 3 21Phase 1/2 18Phase 4 9Phase NA 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 81Thoracic 49Genitourinary 30Breast 28Other hematologic neoplasm 26Lymphoid 23Gynecologic 20Head & Neck 17Dermatologic 13Myeloid 12Sarcoma 10CNS 10Plasma cell 7Tumor-Agnostic 5Endocrine 5Other solid neoplasm 4Other 2NET 2Classical hematology 2

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Everolimus 2Sirolimus 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × NET × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡